ArticleClinical and experimental hepatology2016
Efficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population.
Anna Piekarska et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.